Zacks Investment Research Downgrades BioCryst Pharmaceuticals, Inc. (BCRX) to Hold

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

Several other equities research analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, March 1st. Jefferies Group LLC upped their price target on BioCryst Pharmaceuticals from $3.50 to $6.00 and gave the stock a “positive” rating in a report on Tuesday, February 28th. Ladenburg Thalmann Financial Services assumed coverage on BioCryst Pharmaceuticals in a report on Thursday, February 16th. They set a “buy” rating and a $11.00 price target for the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, February 13th. Finally, FBR & Co reiterated an “outperform” rating on shares of BioCryst Pharmaceuticals in a report on Monday, January 23rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. BioCryst Pharmaceuticals presently has an average rating of “Buy” and an average price target of $8.39.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 3.898% during midday trading on Monday, hitting $9.195. The stock had a trading volume of 1,550,873 shares. The stock’s market cap is $680.02 million. The company has a 50-day moving average price of $6.80 and a 200-day moving average price of $5.62. BioCryst Pharmaceuticals has a 52 week low of $2.48 and a 52 week high of $9.21.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.17. BioCryst Pharmaceuticals had a negative return on equity of 296.19% and a negative net margin of 313.02%. The business earned $9 million during the quarter, compared to the consensus estimate of $4.13 million. During the same quarter in the prior year, the company posted ($0.25) earnings per share. BioCryst Pharmaceuticals’s revenue was up 95.7% compared to the same quarter last year. Equities analysts expect that BioCryst Pharmaceuticals will post ($0.68) EPS for the current year.

Your IP Address:

In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 3,250 shares of the company’s stock in a transaction on Friday, March 10th. The stock was sold at an average price of $9.06, for a total value of $29,445.00. Following the completion of the transaction, the insider now owns 120,563 shares in the company, valued at approximately $1,092,300.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas R. Staab II sold 6,500 shares of the company’s stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $8.43, for a total value of $54,795.00. Following the completion of the transaction, the insider now owns 123,813 shares of the company’s stock, valued at approximately $1,043,743.59. The disclosure for this sale can be found here. Insiders sold a total of 13,000 shares of company stock valued at $109,915 in the last 90 days. Corporate insiders own 5.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $8,420,000. Ellington Management Group LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $110,000. Two Sigma Investments LP acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $255,000. Renaissance Technologies LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $316,000. Finally, Trexquant Investment LP acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $231,000. Hedge funds and other institutional investors own 76.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

5 Day Chart for NASDAQ:BCRX

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/zacks-investment-research-downgrades-biocryst-pharmaceuticals-inc-bcrx-to-hold/1709285.html

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *